Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others.
Tuesday, 22 November 2016
North America HbA1c Testing Devices Market Revenue and Industry Share 2019
Some of the prominent players identified in the global market for hemoglobin A1c testing devices, based on the number of products, include Bio-Rad Laboratories, Inc., Tosoh Corporation, Siemens Healthcare, F. Hoffmann-La Roche Ltd, Alere, Inc., Chek Diagnostics, Danaher Corporation, and Trinity Biotech plc. These prominent players dominate the market for hemoglobin A1c testing devices with their exclusive products.
For example, Bio-Rad Laboratories, Inc., offers devices based on ion-exchange HPLC and boronate affinity chromatography. Its ‘in2in’ point-of-care device is the latest addition with the automated boronate affinity chromatography technique. Additionally, Tososh Corporation offers many HbA1c testing devices based on ion-exchange HPLC technology whereas Siemens Healthcare presents two leading HbA1c testing products with immunoassay technology. According to a report by Transparency Market Research, the global hemoglobin A1c testing market is expected to reach US$1.8 bn by 2019.
POC HbA1c Testing Devices Market Projected for Robust Growth
The global hemoglobin A1c testing devices market is segmented on the basis of end use and technology. Based on end use, this study includes laboratory and point-of-care (POC) testing devices. Laboratory testing devices continue to be the leading segment in the global market by end use and is projected to reach a valuation of US$1.1 bn by 2019. The POC HbA1c testing devices market, on the other hand, is expected to grow at a higher CAGR during the forecast period owing to the rising demand for these devices in developing economies such as India, Brazil, Africa, and others where access to laboratory testing is limited.
Geographically, North America holds the dominant share in the global market for hemoglobin A1c testing devices, owing to high patient awareness levels about HbA1c testing. This market share is, however, is expected to decline by 2019 with Asia Pacific gaining much traction by the end of the forecast period. The report notes that the market in the emerging economies of the Middle East, Africa, and Latin America is driven by factors such as the presence of high unmet healthcare needs, the high prevalence of diabetes, and increasing awareness about the various HbA1c testing technologies.
Exponentially Rising Cases of Diabetics Driving Demand
As per the International Diabetes Federation (IDF), the number of diabetics in the world is projected to reach 642 million by 2040, rising from 415 million in 2015. The report identifies this significant chunk of population as the primary driver in the market for hemoglobin A1c testing devices. Western Pacific and Southeast Asia are projected to have the most number of diabetics by 2035. Moreover, rising geriatric population is another factor that is driving the demand for hemoglobin A1c testing devices. People aged over 55 commonly suffer from diabetes and other endocrine diseases. Furthermore, the diabetes control and complications trial (DCCT) and United Kingdom prospective diabetes study (UKPDS) researches have established the fact that hemoglobin A1c testing on a regular basis improves the health outcome of a diabetes patient. This proven benefit is expected to encourage the market for the same during the forecast period. Conversely, the presence of viable and cost-efficient conventional blood glucose testing is hindering the awareness and concurrent adoption of hemoglobin A1c testing devices, globally.
According to the author of the report, “Emerging economies such as India, China, Philippines, Brazil, and other high growth countries in Asia Pacific, Africa, and the Middle East offer several untapped opportunities. These countries are investing heavily on improving their healthcare infrastructure. Also, the rapid commercialization of devices for diagnosis of diabetes is further fueling the market.”